Whale Bay & Co represents a Nordics based investor that provides flexible Equity Lines to stock listed life science companies. The Equity Line is a financing facility whereby the company gets a discretionary mandate to draw down a tranche of equity on a monthly basis. On average the number of tranches that are provided a range between 24-36. The size of the monthly tranches ranges between EUR 250k and EUR 2mio depending on the market cap and trading volume of the company.
OUR CLIENTS
Cases
OUR CLIENTS
Cases
For a Turkish based specialty pharma client Whale Bay & Co has realized a number of in-licensing deals of premium speciality products. We have supported client with identifying the right opportunities and managed the subsequent in-licensing process.
Our client, a public US-based pharma company, had set the vision to establish themselves as a well-known royalty monetization company. We serve the client as an external business development team. With a high commitment to our client’s strategic goals, we screen and assess licensing agreements, proactively initiate the conversations about royalty monetization opportunities and mediate the negotiations until the agreements are made.
Our client, an innovative Medtech company, approached us to jointly define the company’s product and market positioning, as well as a sound underlying business model to support its next financing round. We applied our market insights and analytics to test different revenue generating models and derived the most beneficial product positioning & business model.
Whale Bay & Co represents a Nordics based investor that provides flexible Equity Lines to stock listed life science companies. The Equity Line is a financing facility whereby the company gets a discretionary mandate to draw down a tranche of equity on a monthly basis. On average the number of tranches that are provided a range between 24-36. The size of the monthly tranches ranges between EUR 250k and EUR 2mio depending on the market cap and trading volume of the company.
For a Turkish based specialty pharma client Whale Bay & Co has realized a number of in-licensing deals of premium speciality products. We have supported client with identifying the right opportunities and managed the subsequent in-licensing process.
Our client, a public US-based pharma company, had set the vision to establish themselves as a well-known royalty monetization company. We serve the client as an external business development team. With a high commitment to our client’s strategic goals, we screen and assess licensing agreements, proactively initiate the conversations about royalty monetization opportunities and mediate the negotiations until the agreements are made.
Our client, an innovative Medtech company, approached us to jointly define the company’s product and market positioning, as well as a sound underlying business model to support its next financing round. We applied our market insights and analytics to test different revenue generating models and derived the most beneficial product positioning & business model.
